Bennet D. Elzey
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
Publications
23
Citations
348
Est. group size
—
Recurring co-author estimate
Active years
10
Publishing since 2016
Bennet D. Elzey's research focuses on prostate cancer biology, particularly castration-resistant prostate cancer (a form of the disease that no longer responds to hormone-lowering therapy). Work in this record examines combination drug strategies, including inhibiting the enzyme Plk1 alongside BET protein blockade, and epigenetic regulation of androgen receptor signaling by protein arginine methyltransferase 5. One associated publication also explores an implantable, ultrasound-powered light source for photodynamic (light-based) cancer therapy.
Publication output was minimal or absent in most years of the past decade but showed a sharp, likely non-representative spike in 2023 tied to a single multi-part publication record.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Data from Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer
2023
- Table S2 from Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer
2023
- Figure S4 from Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer
2023
- Table S1 from Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer
2023
- Figure S5 from Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer
2023
- Figure S1 from Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer
2023
- Figure S3 from Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer
2023
- Figure S2 from Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer
2023
- Table S2 from Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer
2023
- Figure S5 from Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer
2023
- Figure S4 from Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer
2023
- Figure S3 from Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer
2023
- Figure S1 from Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer
2023
- Table S1 from Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer
2023
- Figure S2 from Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer
2023
- Oncogene×1
- Scientific Reports×1
- eLife×1
- Molecular Cancer Therapeutics×1
- bioRxiv (Cold Spring Harbor Laboratory)×1
- Hannah M. Jacobs
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Sandra Torregrosa‐Allen
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Katiri Snyder
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Brittany Sandoval
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Alisha Dhiman
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile